Hepatic impairment No dose adjustment is necessary in individuals with moderate or average (Youngster-Pugh A or B) hepatic impairment (see portion 5.two). Exposure to midostaurin and its Energetic metabolite CGP62221 is substantially decrease in individuals with critical hepatic impairment than that in patients with normal hepatic operate (see section 5. https://busterf186vae9.nytechwiki.com/user